**Question:** Absolute contraindication to thrombolytic therapy is

A. Recent major surgery
B. Active peptic ulcer disease
C. Uncontrolled arterial hypertension
D. Active intracerebral hemorrhage

**Core Concept:** Thrombolytic therapy is a type of medication used to dissolve blood clots, specifically targeting patients with acute ischemic stroke or myocardial infarction. It involves breaking down blood clots (thrombi) by activating plasminogen into plasmin, which degrades fibrin in the clot.

**Why the Correct Answer is Right:** D-Dimers are enzymatic degradation products of cross-linked fibrin, which are released when a blood clot is formed or disrupted. When elevated, they suggest the presence of a blood clot or ongoing clot formation. In the context of thrombolytic therapy, elevated D-Dimers indicate the presence of a blood clot and can be used as a biomarker for clot burden. The correct answer (D) is an absolute contraindication as it presents a situation where the benefits of thrombolytic therapy may not outweigh its risks. In the case of active intracerebral hemorrhage, there is a high risk of rebleeding due to the fragile nature of the blood-brain barrier in the setting of acute brain injury, which can lead to severe disability or death.

**Why Each Wrong Option is Incorrect:**

A. Recent major surgery (Option A) is a relative contraindication, as thrombolytic therapy might still be considered after careful evaluation of the patient's risk-benefit ratio, but it is not an absolute contraindication.

B. Active peptic ulcer disease (Option B) is a relative contraindication, as the risk-benefit ratio should be carefully assessed, but it is not an absolute contraindication.

C. Uncontrolled arterial hypertension (Option C) is a relative contraindication, as the risk-benefit ratio should be carefully assessed, but it is not an absolute contraindication.

**Clinical Pearl:** While thrombolytic therapy has significant benefits in treating acute ischemic stroke or myocardial infarction, absolute contraindications exist when the risk of complications outweigh the potential benefits. This is particularly important when considering thrombolytic therapy in patients with active intracerebral hemorrhage, as the risk of rebleeding is high and can result in severe disability or death. In such cases, a more conservative approach or alternative management strategies may be considered instead.